Annovis to Attend the CTAD 2026 with Three Presentations
Key Highlights
- ➤Annovis will deliver three presentations at CTAD 2026, November 16-19
- ➤Pivotal Phase 3 early Alzheimer’s study design and baseline characteristics will be presented
- ➤Annovis expects pivotal early-2027 buntanetap data readout and prepares New Drug Application
- ➤Presentations cover buntanetap’s mechanism, AI pipeline evaluation, and Phase 3 study updates
Expert Statements
Maria Maccecchini, Founder, President and CEO of Annovis Bio
“Three presentations at CTAD are a testament to our team’s work advancing buntanetap and pushing the Alzheimer’s field forward”
Maria Maccecchini, Founder, President and CEO of Annovis Bio
“Our presentations will cover buntanetap’s innovative mechanism of action, our use of AI for evaluating the Alzheimer’s treatment pipeline, and the updates on our pivotal Phase 3 study in early AD. Together, they reflect our progress as we approach a pivotal data readout in early 2027 and prepare for a New Drug Application. We look forward to sharing all this work and connecting with the Alzheimer’s research community.”
MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will attend and present at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, happening November 16-19 in Boston, MA.
Presentation details: 1. Title: “Restoring proteostasis in Alzheimer's disease with buntanetap, a small-molecule translational inhibitor of neurotoxic proteins” * Presenter: Alexander Morin, PhD, Director, Strategic Communications * Type: Oral communications * Section: Biotech Showcase 7 * Date & time: November 19, 3:52 p.m. ET
Get started
Create a free account to read the full story.